SEP15与胶质瘤患者预后和免疫浸润的关系

侯俊 志1, 张亮 1，, 张白 雪1, 董 静2, 张志 1，
1 华北理工大学；2 唐山工人医院

摘要

摘要：目的：通过生物信息方法分析SEP15与胶质瘤预后和免疫的关系，为SEP15在胶质瘤中的诊断和治疗提供依据。方法:我们从UCSC数据库中下载了经统一标准化的泛癌数据集,使用R软件包survival的survfit分析SEP15对胶质瘤预后的影响，R软件包ESTIMATE、IOBR分析SEP15与胶质瘤免疫浸润的关系。结果：差异分析表明，SEP15在肿瘤患者中表达量高于正常人，生存分析表明，SEP15高表达对胶质瘤预后不利，此外瀑布图显示，SEP15低表达的患者往往伴随着IDH1突变。免疫浸润分析表明，SEP15与胶质瘤免疫微环境密切相关，其可能通过B细胞、中性粒细胞、巨噬细胞、树突状细胞在胶质瘤中发挥作用。结论：SEP15是一个新的胶质瘤诊断和预后的因子。

关键词

关键词：胶质瘤；SEP15；免疫浸润；生存分析

参考

[1] Ostrom QT, Gittleman H, Truitt G, Boscia A, Kruchko C, Barnholtz-Sloan JS. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015. Neuro Oncol. 2018 Oct 1;20(suppl_4):iv1-iv86. doi: 10.1093/neuonc/noy131. Erratum in: Neuro Oncol. 2018 Nov 17;:null. PMID: 30445539; PMCID: PMC6129949.[2] Zhang N, Zhang L, Qiu B, Meng L, Wang X, Hou BL. Correlation of volume transfer coefficient Ktrans with histopathologic grades of gliomas. J Magn Reson Imaging. 2012 Aug;36(2):355-63. doi: 10.1002/jmri.23675. Epub 2012 May 11. PMID: 22581762; PMCID: PMC3399966.[3] Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021 Aug 2;23(8):1231-1251. doi: 10.1093/neuonc/noab106. PMID: 34185076; PMCID: PMC8328013.[4] Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009 May;10(5):459-66. doi: 10.1016/S1470-2045(09)70025-7. Epub 2009 Mar 9. PMID: 19269895.[5] Kumaraswamy E, Malykh A, Korotkov KV, Kozyavkin S, Hu Y, Kwon SY, Moustafa ME, Carlson BA, Berry MJ, Lee BJ, Hatfield DL, 临床研究45医学研究Diamond AM, Gladyshev VN. Structure-expression relationships of the 15-kDa selenoprotein gene. Possible role of the protein in cancer etiology. J Biol Chem. 2000 Nov 10;275(45):35540-7. doi: 10.1074/jbc.M004014200. PMID: 10945981.[6] Apostolou S, Klein JO, Mitsuuchi Y, Shetler JN, Poulikakos PI, Jhanwar SC, Kruger WD, Testa JR. Growth inhibition and induction of apoptosis in mesothelioma cells by selenium and dependence on selenoprotein SEP15 genotype. Oncogene. 2004 Jun 24;23(29):5032-40. doi: 10.1038/sj.onc.1207683. PMID: 15107826.[7]Apostolou S, De Rienzo A, Murthy SS, Jhanwar SC, Testa JR. Absence of BCL10 mutations in human malignant mesothelioma. Cell. 1999 Jun 11;97(6):684-6; discussion 686-8. doi: 10.1016/s0092-8674(02)09765-9. PMID: 10380921.[8] Tsuji PA, Carlson BA, Yoo MH, Naranjo-Suarez S, Xu XM, He Y, Asaki E, Seifried HE, Reinhold WC, Davis CD, Gladyshev VN, Hatfield DL. The 15kDa selenoprotein and thioredoxin reductase 1 promote colon cancer by different pathways. PLoS One. 2015 Apr 17;10(4):e0124487. doi: 10.1371/journal.pone.0124487. PMID: 25886253; PMCID: PMC4401539.[9] Tsuji PA, Carlson BA, Naranjo-Suarez S, Yoo MH, Xu XM, Fomenko DE, Gladyshev VN, Hatfield DL, Davis CD. Knockout of the 15 kDa selenoprotein protects against chemically-induced aberrant crypt formation in mice. PLoS One. 2012;7(12):e50574. doi: 10.1371/journal.pone.0050574. Epub 2012 Dec 4. PMID: 23226526; PMCID: PMC3514276.[10]Gresner P, Gromadzinska J, Jablonska E, Kaczmarski J, Wasowicz W. Expression of selenoprotein-coding genes SEPP1, SEP15 and hGPX1 in non-small cell lung cancer. Lung Cancer. 2009 Jul;65(1):34-40. doi: 10.1016/j.lungcan.2008.10.023. Epub 2008 Dec 6. PMID: 19058871.[11] Reszka E. Selenoproteins in bladder cancer. Clin Chim Acta. 2012 May 18;413(9-10):847-54. doi: 10.1016/j.cca.2012.01.041. Epub 2012 Feb 12. PMID: 22349600.[12] Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009 Feb 19;360(8):765-73. doi: 10.1056/NEJMoa0808710. PMID: 19228619; PMCID: PMC2820383.[13] Rossetto M, Ciccarino P, Boisselier B, Labussiere M, Sanson M. Metabolism of glioma and IDH1/IDH2 mutations. Rev Neurol (Paris). 2011 Oct;167(10):699-703. doi: 10.1016/j.neurol.2011.08.002. Epub 2011 Aug 31. PMID: 21885076.[14] Nobusawa S, Watanabe T, Kleihues P, Ohgaki H. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res. 2009 Oct 1;15(19):6002-7. doi: 10.1158/1078-0432.CCR-09-0715. Epub 2009 Sep 15. PMID: 19755387.[15] Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducray F, El Hallani S, Boisselier B, Mokhtari K, Hoang-Xuan K, Delattre JY. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol. 2009 Sep 1;27(25):4150-4. doi: 10.1200/JCO.2009.21.9832. Epub 2009 Jul 27. PMID: 19636000.[16] Barthel L, Hadamitzky M, Dammann P, Schedlowski M, Sure U, Thakur BK, Hetze S. Glioma: molecular signature and crossroads with tumor microenvironment. Cancer Metastasis Rev. 2022 Mar;41(1):53-75. doi: 10.1007/s10555-021-09997-9. Epub 2021 Oct 23. PMID: 34687436; PMCID: PMC8924130.[17] Wei J, Chen P, Gupta P, Ott M, Zamler D, Kassab C, Bhat KP, Curran MA, de Groot JF, Heimberger AB. Immune biology of glioma-associated macrophages and microglia: functional and therapeutic implications. Neuro Oncol. 2020 Feb 20;22(2):180-194. doi: 10.1093/neuonc/noz212. PMID: 31679017; PMCID: PMC7442334.[18] Sokratous G, Polyzoidis S, Ashkan K. Immune infiltration of tumor microenvironment following immunotherapy for glioblastoma multiforme. Hum Vaccin Immunother. 2017 Nov 2;13(11):2575-2582. doi: 10.1080/21645515.2017.1303582. Epub 2017 Mar 31. PMID: 28362548; PMCID: PMC5703406.